FIELD: medicine.
SUBSTANCE: invention relates to a method for protection of cortical neurons from a mitochondrial disfunction, toxicity, or oxygen and glucose deprivation, including the administration to a patient who needs it of effective amount of lithium benzoate, where effective amount of lithium benzoate is from 100 to 1000 mg.
EFFECT: obtaining a method for the treatment of disorders of the central nervous system.
12 cl, 21 dwg, 2 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING BENZOATE COMPOUND AND TANNIC ACID FOR TREATMENT OF DISORDER OF CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2756812C2 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASE | 2012 |
|
RU2618412C2 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURONS OR NEURODEGENERATION | 2011 |
|
RU2722018C2 |
| ANALOGUES OF CYSTAMINE, USED FOR PARKINSON'S DISEASE TREATMENT | 2012 |
|
RU2630583C2 |
| THERAPY FOR STIMULATION OF CELL GROWTH | 2010 |
|
RU2586302C2 |
| VACCINE AND METHOD FOR TREATING MOTOR NEURON DISEASES | 2002 |
|
RU2303996C2 |
| METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE | 2011 |
|
RU2660348C2 |
| USING MESENCHYMAL AND NEURONAL MARKER EXPRESSING STEM CELLS AND THEIR COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES (VERSIONS) | 2017 |
|
RU2742828C2 |
| METHODS AND COMPOSITIONS FOR DELIVERY OF IDURONATE-2-SULPHATASE TO CNS | 2011 |
|
RU2774112C2 |
